Dr. Smith spoke at the Fletcher Allen Health Care Center at the University of Vermont.
Subsequently, Dr. Smith presented data obtained from the baseline visit of patients enrolled in the Nuedexta Bulbar Function treatment trial at the annual meeting of the American Academy of Neurology. As of May 2nd, 43 persons out of a planned enrollment of 60 were enrolled in the nationwide treatment trial that is being conducted at seven ALS centers.
Comments